Merck Animal Health Partners with World Veterinary Education in Production Animal Health to Support Continuing Veterinarian Education
Post-Graduate Study Programs Support Today’s Poultry Field Veterinary Leaders
MADISON, NJ, October 6, 2016 – Merck Animal Health (known as MSD Animal Health outside the US and Canada) today announced a new partnership with World Veterinary Education in Production Animal Health (WVEPAH), a global non-profit organization providing World Organization for Animal Health (OIE) validated, post-graduate study programs for professionals in various aspects of production animal health, including poultry. As part of the partnership, Merck Animal Health will help facilitate the certification of 38 professionals worldwide by the end of 2016.
“Merck Animal Health is proud to extend our commitment to veterinarians and poultry producers by facilitating new educational opportunities to help them achieve effective solutions and improve the health of their animals,” said Delair Bolis, executive director, Global Poultry, Merck Animal Health.
“Through our post-graduate study programs, we are providing training to support today’s poultry field veterinary leaders,” said Pierre Cadot, M.D., director, WVEPAH. “The growing worldwide demand for poultry products can only be met by improving poultry health and welfare, as well as producers’ productivity and profitability, and we are pleased to partner with MSD Animal Health to build upon our knowledge base in the field of poultry production.”
Founded in 2010, WVEPAH offers Certification and Masters programs to improve professionals’ knowledge of production animal health. The examination for the “Certificate in Animal Health: Poultry Production” requires participation in specialized modules related to the regulatory aspects of OIE poultry health. The Masters program requires graduation from the Certificate program in addition to a second specialized module.
Upcoming modules in “Turkey” (October 17-22, 2016 in Berlin) and “Chicken” (November 21 – December 1, 2016 in Gaborone, Botswana) are open for registration. Additional courses are planned in 2017.
To register for a course or find more information, please visit the WVEPAH website at www.wvepah.org.
About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).